Abstract
Background Eye movement abnormalities are paramount in neurological disorders. However, unaided eye movement assessments lack granularity. Although videooculography (VOG) improves diagnostic accuracy, resource intensiveness preclude its broad use. To bridge this care gap, we here validate a framework for smartphone video-based nystagmography capitalizing on recent computer vision advances.
Methods A recurrent convolutional network was fine-tuned for pupil tracking using >550 annotated frames: ConVNG. Slow phase velocity of optokinetic nystagmus was calculated in 10 subjects using both ConVNG and VOG. Equivalence of accuracy and precision was assessed using the “two one-sample t-test” (TOST) and Bayesian interval-null approaches.
Results ConVNG tracking accuracy reached 9-15% of an average pupil diameter. SPV measurement accuracy was equivalent to VOG (p< .017; Bayes factors (BF) > 24). Average precision was 0.30° for ConVNG and 0.12° for VOG.
Conclusions ConVNG enables smartphone video nystagmography with an accuracy comparable to VOG and precision approximately one order of magnitude higher than comparable ARKit applications. This serves as a blueprint for highly accessible tools with potential to accelerate progress toward precise and personalized Medicine.
Competing Interest Statement
MF, JH, MB, JT and RP report no conflicts of interest. JV reports grants and personal fees from Medtronic Inc., grants and personal fees from Boston Scientific, personal fees from St. Jude, outside the submitted work. ES is the developer of EyeSeeCam and CEO of EyeSeeTec. DZ received compensation for scientific consultancy from Novartis, for advisory boards from Biogen, and for training activities from Desitin, outside the submitted work.
Funding Statement
MF receives funding from the Interdisciplinary Center for Clinical Research (IZKF) Z2-CSP13 at the University Hospital Wuerzburg. JV was supported by the German Research Foundation (DFG, Project-ID 424778381, TRR 295). DZ receives funding from the Interdisciplinary Center for Clinical Research (IZKF) AdvCSP-4 at the University Hospital Wuerzburg.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from Julius-Maximilians University Wuerzburg's ethics committee under the number 318/21.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.